TY - JOUR
T1 - Surgical site infections in orthopedic surgery
T2 - The effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study
AU - Kalmeijer, M. D.
AU - Coertjens, H.
AU - Van Nieuwland-Bollen, P. M.
AU - Bogaers-Hofman, D.
AU - De Baere, G. A.J.
AU - Stuurman, A.
AU - Van Belkum, A.
AU - Kluytmans, J. A.J.W.
PY - 2002/8/15
Y1 - 2002/8/15
N2 - The objective of this study was to determine whether use of mupirocin nasal ointment for perioperative eradication of Staphylococcus aureus nasal carriage is effective in preventing the development of surgical site infections (SSIs). A randomized, double-blind, placebo-controlled design was used. Either mupirocin or placebo nasal ointment was applied twice daily to 614 assessable patients from the day of admission to the hospital until the day of surgery. A total of 315 and 299 patients were randomized to receive mupirocin and placebo, respectively. Eradication of nasal carriage was significantly more effective in the mupirocin group (eradication rate, 83.5% versus 27.8%). In the mupirocin group, the rate of endogenous S. aureus infections was 5 times lower than in the placebo group (0.3% and 1.7%, respectively; relative risk, 0.19; 95% confidence interval, 0.02-1.62). Mupirocin nasal ointment did not reduce the SSI rate (by S. aureus) or the duration of hospital stay.
AB - The objective of this study was to determine whether use of mupirocin nasal ointment for perioperative eradication of Staphylococcus aureus nasal carriage is effective in preventing the development of surgical site infections (SSIs). A randomized, double-blind, placebo-controlled design was used. Either mupirocin or placebo nasal ointment was applied twice daily to 614 assessable patients from the day of admission to the hospital until the day of surgery. A total of 315 and 299 patients were randomized to receive mupirocin and placebo, respectively. Eradication of nasal carriage was significantly more effective in the mupirocin group (eradication rate, 83.5% versus 27.8%). In the mupirocin group, the rate of endogenous S. aureus infections was 5 times lower than in the placebo group (0.3% and 1.7%, respectively; relative risk, 0.19; 95% confidence interval, 0.02-1.62). Mupirocin nasal ointment did not reduce the SSI rate (by S. aureus) or the duration of hospital stay.
UR - http://www.scopus.com/inward/record.url?scp=0037103319&partnerID=8YFLogxK
U2 - 10.1086/341025
DO - 10.1086/341025
M3 - Article
C2 - 12145715
AN - SCOPUS:0037103319
SN - 1058-4838
VL - 35
SP - 353
EP - 358
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -